Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4869865
Max Phase: Preclinical
Molecular Formula: C52H69F12N13O15
Molecular Weight: 888.09
Molecule Type: Unknown
Associated Items:
ID: ALA4869865
Max Phase: Preclinical
Molecular Formula: C52H69F12N13O15
Molecular Weight: 888.09
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@@H](CCCN)C(=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NCCN1CCN(C(=O)CC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C44H65N13O7.4C2HF3O2/c1-29(40(61)53-43(64)35(11-7-17-45)51-30(2)58)50-42(63)34(12-8-18-49-44(46)47)48-19-22-54-23-25-56(26-24-54)38(59)27-31-15-20-55(21-16-31)28-39(60)57-36-13-5-3-9-32(36)41(62)52-33-10-4-6-14-37(33)57;4*3-2(4,5)1(6)7/h3-6,9-10,13-14,29,31,34-35,48H,7-8,11-12,15-28,45H2,1-2H3,(H,50,63)(H,51,58)(H,52,62)(H4,46,47,49)(H,53,61,64);4*(H,6,7)/t29-,34-,35-;;;;/m0..../s1
Standard InChI Key: RPRUFSOEDUIPNK-DCZAANBCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 888.09 | Molecular Weight (Monoisotopic): 887.5130 | AlogP: -0.22 | #Rotatable Bonds: 20 |
Polar Surface Area: 280.52 | Molecular Species: BASE | HBA: 12 | HBD: 9 |
#RO5 Violations: 3 | HBA (Lipinski): 20 | HBD (Lipinski): 11 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 11.98 | CX LogP: -3.08 | CX LogD: -7.35 |
Aromatic Rings: 2 | Heavy Atoms: 64 | QED Weighted: 0.05 | Np Likeness Score: -0.46 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):